
AdvaMed® Comments on FDA-2016-D-1307 Communications with Payors
AdvaMed’s recent submission to the Food and Drug Administration (FDA) provides comments on the Agency’s revised draft guidance governing communications between drug and device manufacturers and payors, formulary committees, and…





